BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Using matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS), the plasma protein profile was determined in nine stage IV CRC patients (study group) and nine clean-colon healthy subjects (control group).

[MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / analysis. Colorectal Neoplasms / blood. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17117375.001).

[ISSN] 1076-5174

[Journal-full-title] Journal of mass spectrometry : JMS

[ISO-abbreviation] J Mass Spectrom

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We wished to ascertain whether a correlation exists between the expression of EGFR and treatment outcome in a group of patients with rectal adenocarcinoma who had undergone preoperative radiotherapy (RT).

Initial staging showed 75% and 25% stage II and III tumors, respectively.

Genetic Alliance. consumer health - Rectal Cancer.

MedlinePlus Health Information. consumer health - Radiation Therapy.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):29-35 [9588914.001]

[Cites] Br J Cancer. 2005 Jun 20;92(12):2114-21 [15956964.001]

[Cites] Radiat Res. 2000 Mar;153(3):245-57 [10669545.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32 [10760290.001]

[Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]

[Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):410-8 [11567815.001]

[Cites] Eur J Cancer. 2001 Nov;37(17):2169-77 [11677103.001]

[Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]

[Cites] Clin Cancer Res. 2002 Mar;8(3):885-92 [11895923.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1460-5 [12459370.001]

[Cites] Cancer Res. 2002 Dec 15;62(24):7350-6 [12499279.001]

[Cites] Semin Radiat Oncol. 2003 Jan;13(1):22-30 [12520461.001]

[Cites] Semin Radiat Oncol. 2003 Oct;13(4):403-18 [14586830.001]

[Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):11-20 [15093894.001]

[Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]

[Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(20):7159-63 [2890160.001]

[Cites] Surgery. 1990 Oct;108(4):787-92; discussion 792-3 [2218892.001]

[Cites] Br J Surg. 1990 Dec;77(12):1352-4 [2276016.001]

[Cites] Head Neck. 1991 Mar-Apr;13(2):132-9 [2022478.001]

[Cites] Clin Otolaryngol Allied Sci. 1991 Oct;16(5):466-9 [1742894.001]

[Cites] Surg Gynecol Obstet. 1992 Jan;174(1):27-32 [1729745.001]

[Cites] Hum Pathol. 1992 Sep;23(9):974-9 [1355464.001]

[Cites] Cancer. 1993 Apr 15;71(8):2454-60 [8095852.001]

[Cites] Surg Today. 1993;23(1):21-30 [8461602.001]

[Cites] J Pathol. 1993 Mar;169(3):323-8 [8492225.001]

[Cites] J Clin Oncol. 1993 Oct;11(10):1873-8 [8410112.001]

[Cites] J Cell Biochem Suppl. 1993;17F:188-91 [8412192.001]

[Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):91-8 [8083133.001]

[Cites] J Biol Chem. 1996 Apr 19;271(16):9185-8 [8621573.001]

[Cites] Br J Surg. 1996 Mar;83(3):375-9 [8665198.001]

[Cites] Laryngoscope. 1996 Jul;106(7):884-8 [8667988.001]

[Cites] Br J Surg. 1996 Jun;83(6):781-5 [8696739.001]

[Cites] Eur J Surg. 1996 Aug;162(8):643-8 [8891623.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13704-8 [8942998.001]

[Cites] Biochim Biophys Acta. 1996 Nov 8;1314(1-2):147-56 [8972728.001]

[Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]

[Cites] Int J Colorectal Dis. 1997;12(1):19-23 [9112145.001]

[Cites] FEBS Lett. 1997 Jun 23;410(1):83-6 [9247128.001]

[Cites] Pathology. 1997 Aug;29(3):251-4 [9271009.001]

[Cites] Oncogene. 1997 Sep 4;15(10):1191-7 [9294612.001]

[Cites] Radiat Oncol Investig. 1997;5(4):180-6 [9327497.001]

[Cites] Biochim Biophys Acta. 1997 Oct 11;1358(3):289-99 [9366260.001]

[Cites] Radiat Res. 1998 Jun;149(6):579-87 [9611096.001]

[Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):585-91 [9635706.001]

[Cites] Oncogene. 1998 May 28;16(21):2787-96 [9652746.001]

[Cites] J Pathol. 1998 Jun;185(2):167-74 [9713343.001]

[Cites] Int J Cancer. 1999 Apr 20;84(2):188-91 [10096253.001]

[Cites] Br J Cancer. 1999 Apr;79(11-12):1864-9 [10206306.001]

[Cites] Mol Biol Cell. 1999 Aug;10(8):2493-506 [10436007.001]

[Cites] Clin Cancer Res. 1999 Oct;5(10):2884-90 [10537357.001]

(PMID = 15967033.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor

[Other-IDs] NLM/ PMC1185521

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: In a province-wide audit of patients undergoing treatment for rectal cancer in British Columbia in 1996, the 4-year rate of pelvic recurrence for stage 3 rectal cancer was 27%.

Relative to the 1996 cohort, there was a decreasing trend in 2-year overall pelvic recurrence rates in the 2003/04 cohort (9.6% v. 6.9%) and a significant decrease in recurrence among patients with stage 3 cancers (18.2% v. 9.2%; p = 0.020).

[MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / therapeutic use. Colectomy / methods. Rectal Neoplasms / therapy

Genetic Alliance. consumer health - Rectal Cancer.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cochrane Database Syst Rev. 2000;(2):CD000125 [10796491.001]

[Cites] Can J Surg. 2010 Aug;53(4):222-4 [20646394.001]

[Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]

[Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]

[Cites] J Clin Oncol. 2002 Apr 1;20(7):1729-34 [11919228.001]

[Cites] Am J Surg. 2002 May;183(5):504-8 [12034381.001]

[Cites] Dis Colon Rectum. 2002 Jul;45(7):857-66 [12130870.001]

[Cites] BMJ. 2003 Jul 5;327(7405):33-5 [12842955.001]

[Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]

[Cites] JAMA. 1999 Sep 1;282(9):867-74 [10478694.001]

[Cites] J Clin Oncol. 2005 Dec 20;23(36):9257-64 [16361623.001]

[Cites] Br J Surg. 2006 Oct;93(10):1215-23 [16983741.001]

[Cites] Br J Surg. 2007 Oct;94(10):1285-92 [17661309.001]

[Cites] Ann Surg. 2007 Nov;246(5):693-701 [17968156.001]

[CommentIn] Can J Surg. 2010 Aug;53(4):222-4 [20646394.001]

(PMID = 20646395.001).

[ISSN] 1488-2310

[Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie

[ISO-abbreviation] Can J Surg

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Canada

[Chemical-registry-number] 0 / Antineoplastic Agents

[Other-IDs] NLM/ PMC2912013

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Nine tumors were located in the rectum, two in the sigmoid, and each one in the transverse colon and cecum, respectively.

All patients were advanced at the time of diagnosis, with AJCC TNM staging: stage IIIB (n=2), stage IIIC (n=3), and stage IV (n=8).

Five patients who received chemotherapy showed median survival of 32 months (stage III) and 17.5 months (stage IV), whereas other five patients without chemotherapy died with a median survival of 6.2 months.

[MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biopsy. Chromogranin A / analysis. Chromogranin A / immunology. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Synaptophysin / analysis. Synaptophysin / immunology

Genetic Alliance. consumer health - Pancreatic islet cell tumors.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16929153.001).

[ISSN] 1598-9992

[Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

[ISO-abbreviation] Korean J Gastroenterol

[Language] kor

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Korea (South)

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Stage IV endometriosis with extensive pelvic involvement was found in two patients.

Intraoperatively, the endometriotic lesions involved the ovaries (all cases); Cul de sac (four cases); urinary bladder (two cases); sigmoid colon, hemidiaphragms, and uterine vessels (one case each).

The endometriotic lesions were associated with uterine leiomyomas (two patients) and adenocarcinoma of the vagina (one patient).

One patient had recurred with metastatic adenocarcinoma of the vault.

Genetic Alliance. consumer health - Endometriosis.

MedlinePlus Health Information. consumer health - Endometriosis.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

MedlinePlus Health Information. consumer health - Pelvic Pain.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Eur J Clin Invest. 2002 Mar;32(3):199-206 [11895472.001]

[Cites] Cancer Sci. 2007 Mar;98(3):387-91 [17270029.001]

[Cites] Fertil Steril. 2005 Jul;84(1):12-5 [16009147.001]

[Cites] Mod Pathol. 2006 Dec;19(12):1615-23 [16980942.001]

[Cites] Int J Gynecol Pathol. 2000 Jul;19(3):276-9 [10907178.001]

[Cites] J Reprod Immunol. 2005 Feb;65(1):55-63 [15694967.001]

[Cites] Hum Pathol. 2007 Jul;38(7):1074-80 [17442376.001]

[Cites] Ann N Y Acad Sci. 2002 Mar;955:281-92; discussion 293-5, 396-406 [11949955.001]

[Cites] Dis Markers. 2007;23(5-6):367-76 [18057520.001]

[Cites] Eur J Obstet Gynecol Reprod Biol. 2007 Sep;134(1):83-6 [16844279.001]

[Cites] Arch Pathol Lab Med. 2003 Aug;127(8):1003-6 [12873175.001]

[Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):466-71 [12911723.001]

[Cites] Zhonghua Bing Li Xue Za Zhi. 2001 Jun;30(3):169-72 [11866970.001]

[Cites] Adv Anat Pathol. 2007 Jul;14(4):241-60 [17592255.001]

[Cites] Diagn Cytopathol. 2002 Dec;27(6):379-81 [12451571.001]

[Cites] Hum Reprod. 2001 Dec;16(12):2668-71 [11726593.001]

[Cites] Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):239-42 [14505256.001]

[Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Jan;82(1):85-7 [10192492.001]

[Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:39-43 [11093060.001]

[Cites] Int J Gynecol Pathol. 2003 Jan;22(1):42-51 [12496697.001]

[Cites] Fertil Steril. 2002 Oct;78(4):743-9 [12372450.001]

[Cites] Mod Pathol. 2006 Jan;19(1):83-9 [16258507.001]

[Cites] Zhonghua Fu Chan Ke Za Zhi. 2006 Feb;41(2):111-3 [16640860.001]

[Cites] Am J Clin Pathol. 1999 Feb;111(2):248-51 [9930148.001]

[Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:2-10 [11093055.001]

[Cites] Am J Obstet Gynecol. 2001 Jun;184(7):1407-11; discussion 1411-3 [11408860.001]

[Cites] Arch Pathol Lab Med. 2007 Jan;131(1):138-44 [17227115.001]

[Cites] Int J Gynecol Cancer. 2003 May-Jun;13(3):376-80 [12801273.001]

[Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Jul 1;109(1):97-101 [12818453.001]

[Cites] Pathol Res Pract. 2006;202(6):433-7 [16513291.001]

[Cites] Diagn Cytopathol. 1996 Jun;14(4):331-3 [8725135.001]

[Cites] Int J Gynecol Pathol. 2007 Jul;26(3):345-51 [17581423.001]

[Cites] Ginekol Pol. 2001 May;72(5):268-72 [11526755.001]

[Cites] J Med Genet. 2006 Jan;43(1):84-90 [15930087.001]

[Cites] Int J Gynecol Pathol. 2006 Jul;25(3):223-9 [16810057.001]

[Cites] Reproduction. 2001 Apr;121(4):581-6 [11277878.001]

[Cites] Am J Surg Pathol. 2004 Mar;28(3):285-97 [15104291.001]

[Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:44-50 [11093061.001]

[Cites] Am J Surg Pathol. 2007 Oct;31(10):1490-501 [17895749.001]

[Cites] Int J Gynecol Pathol. 2002 Oct;21(4):401-6 [12352189.001]

[Cites] Med Electron Microsc. 2004 Jun;37(2):97-100 [15221651.001]

[Cites] Zhonghua Fu Chan Ke Za Zhi. 2000 Nov;35(11):667-9 [11218895.001]

[Cites] Am J Obstet Gynecol. 2004 Nov;191(5):1725-7 [15547552.001]

(PMID = 18575828.001).

[ISSN] 1219-4956

[Journal-full-title] Pathology oncology research : POR

[ISO-abbreviation] Pathol. Oncol. Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Here, we report on the prevalence and potential clinical significance of fascin expression in relation to the progression of colorectal adenocarcinoma and to tumor cell proliferation as measured by Ki67 index.

In the clinically-annotated tumors, fascin immunoreactivity was more common in tumors located in the proximal colon (p = 0.009), but was not associated with age, gender, or TNM stage.

Patients with stage III/IV adenocarcinomas (n = 62) with strong fascin immunoreactivity had a worse prognosis than patients with low or absent fascin, (3-year overall survival of 11% versus 43% for fascin-negative patients; p = 0.023).

Strong and diffuse expression was seen in a subset of advanced colorectal adenocarcinomas that correlated with shorter survival in stage III and IV patients.

[MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Carrier Proteins / biosynthesis. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic / physiology. Microfilament Proteins / biosynthesis

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]

[Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]

[Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]

[Cites] Am J Pathol. 2000 Dec;157(6):1947-53 [11106567.001]

[Cites] Curr Opin Oncol. 2001 Jan;13(1):63-9 [11148689.001]

[Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]

[Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]

[Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]

[Cites] Am J Pathol. 2001 Nov;159(5):1613-7 [11696421.001]

[Cites] J Clin Oncol. 2002 Feb 15;20(4):1043-8 [11844828.001]

[Cites] Int J Biochem Cell Biol. 2002 Jun;34(6):685-98 [11943599.001]

[Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]

[Cites] Cancer Cell. 2002 Apr;1(3):233-6 [12086859.001]

[Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]

[Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]

[Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]

[Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]

[Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]

[Cites] Oncogene. 2003 Jun 5;22(23):3616-23 [12789270.001]

[Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]

[Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]

[Cites] Curr Opin Cell Biol. 2004 Feb;16(1):14-23 [15037300.001]

[Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]

[Cites] Curr Opin Cell Biol. 2004 Oct;16(5):590-6 [15363811.001]

[Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]

[Cites] Gene Expr Patterns. 2004 Oct;4(6):637-43 [15465486.001]

[Cites] Cell. 1996 Feb 9;84(3):345-57 [8608588.001]

[Cites] Science. 1996 May 24;272(5265):1187-90 [8638166.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13927-31 [9391129.001]

[Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]

[Cites] Semin Cancer Biol. 1999 Aug;9(4):245-54 [10448112.001]

[Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]

[Cites] J Surg Oncol. 2004 Dec 15;88(4):261-6 [15565587.001]

[Cites] Hum Genomics. 2004 Jan;1(2):134-40 [15601541.001]

[Cites] Curr Opin Genet Dev. 2005 Feb;15(1):87-96 [15661538.001]

[Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]

[Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]

[Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]

[Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]

[Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]

[Cites] Clin Cancer Res. 2006 Mar 1;12(5):1533-9 [16533778.001]

[ErratumIn] BMC Cancer. 2011;11:488

(PMID = 17029629.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin

[Other-IDs] NLM/ PMC1615879

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The lesion was judged to be P1, SE, H0, N2 and Stage IV and the patient was managed on a regular schedule as an outpatient.

A fiber optic examination of the sigmoid colon detected an ulcerous lesion with a hemorrhage at the anterior rectal wall.

A biopsy revealed the lesion to be Group V poorly differentiated adenocarcinoma.

After 3 courses of this regimen, a fiber optic examination of the colon conducted in February 2005 no longer detected the rectal tumor, leaving only a cicatrix.

[MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Diseases / drug therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / secondary. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

Genetic Alliance. consumer health - Rectal Cancer.

MedlinePlus Health Information. consumer health - Rectal Disorders.

MedlinePlus Health Information. consumer health - Stomach Cancer.

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16315933.001).

[ISSN] 0385-0684

[Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy

[ISO-abbreviation] Gan To Kagaku Ryoho

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In a multivariate analysis, T-stage, N-stage, and tumor location were independent risk factors for CRM.

T-stage, N-stage, and CRM were risk factors for LR and age, T-stage, N-stage, CRM, and distance of the inferior tumor margin to the anal verge for OS.

CONCLUSION: Age, T-stage, N-stage, CRM, distance of the tumor to the anal verge, and tumor location were independent risk factors for adverse outcome in patients treated with an APR for low rectal cancer.

[MeSH-major] Adenocarcinoma / surgery. Digestive System Surgical Procedures / methods. Postoperative Complications. Rectal Neoplasms / surgery

Genetic Alliance. consumer health - Rectal Cancer.

MedlinePlus Health Information. consumer health - After Surgery.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]

[Cites] Ann Oncol. 2006 Aug;17(8):1239-48 [16873440.001]

[Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]

[Cites] J Clin Oncol. 2001 Apr 1;19(7):1976-84 [11283130.001]

[Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]

[Cites] Am J Surg Pathol. 2002 Mar;26(3):350-7 [11859207.001]

[Cites] Dis Colon Rectum. 2002 Jul;45(7):857-66 [12130870.001]

[Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1311-20 [12654443.001]

[Cites] Br J Surg. 2003 May;90(5):583-92 [12734867.001]

[Cites] Colorectal Dis. 2003 Mar;5(2):180-4 [12780910.001]

[Cites] Radiother Oncol. 2004 Jul;72(1):15-24 [15236870.001]

[Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]

[Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]

[Cites] Int J Colorectal Dis. 1988 Jun;3(2):127-31 [3045231.001]

[Cites] Lancet. 1994 Sep 10;344(8924):707-11 [7915774.001]

[Cites] Colorectal Dis. 2005 Jul;7(4):410-6 [15932569.001]

[Cites] Ann Surg. 2005 Jul;242(1):74-82 [15973104.001]

[Cites] J Clin Oncol. 2005 Aug 20;23(24):5620-7 [16009958.001]

[Cites] Eur J Surg Oncol. 2005 Oct;31(8):845-53 [15979269.001]

[Cites] J Clin Oncol. 2005 Dec 20;23(36):9257-64 [16361623.001]

[Cites] Br J Surg. 2006 Jan;93(1):105-12 [16302179.001]

[Cites] Dis Colon Rectum. 2005 Dec;48(12):2249-57 [16400512.001]

[Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):323-7 [10661338.001]

(PMID = 17592295.001).

[ISSN] 0003-4932

[Journal-full-title] Annals of surgery

[ISO-abbreviation] Ann. Surg.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ PMC1899206

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The localization of each PGES and COX-2 protein was examined by immunohistochemistry in 155 surgical resections and correlated to clinicopathological factors and patient prognosis. mPGES-1 mRNA and protein levels were significantly higher in CRC than in paired normal tissues. mPGES-1 immunoreactivity localized in cancer cells in 43% of cases. mPGES-2 immunoreactivity was significantly more pronounced in cancer cells than in adjacent normal epithelium in 36% of cases. cPGES immunoreactivity was homogeneous in cancer cells and thus determined constitutive. mPGES-1 and mPGES-2 correlated with significantly worse prognosis in stage I-III patients.

[MeSH-major] Adenocarcinoma / enzymology. Colorectal Neoplasms / enzymology. Intramolecular Oxidoreductases / metabolism. Microsomes / enzymology

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]

[Cites] J Biol Chem. 2002 May 10;277(19):16355-64 [11847219.001]

[Cites] Mol Carcinog. 2006 Jun;45(6):447-54 [16688727.001]

[Cites] J Biochem Mol Biol. 2005 Nov 30;38(6):633-8 [16336776.001]

[Cites] Cancer Res. 1998 Feb 1;58(3):409-12 [9458081.001]

[Cites] Biochem Biophys Res Commun. 2002 Mar 8;291(4):884-9 [11866447.001]

[Cites] J Biol Chem. 2003 Sep 26;278(39):37937-47 [12835322.001]

[Cites] J Immunol. 2001 Jul 1;167(1):469-74 [11418684.001]

[Cites] Gut. 2006 Jan;55(1):54-61 [16085694.001]

[Cites] Gut. 2006 Jan;55(1):115-22 [16118353.001]

[Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]

[Cites] N Engl J Med. 2007 May 24;356(21):2131-42 [17522398.001]

[Cites] J Biol Chem. 2000 Oct 20;275(42):32783-92 [10869354.001]

[Cites] Br J Pharmacol. 2004 Apr;141(7):1091-7 [15023855.001]

[Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]

[Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7220-5 [10377395.001]

[Cites] Biochem Biophys Res Commun. 2008 Jul 18;372(1):249-53 [18485889.001]

[Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):63-75 [15000150.001]

[Cites] Hum Pathol. 2007 Dec;38(12 ):1826-35 [17868774.001]

[Cites] Clin Cancer Res. 2005 Jul 1;11(13):4754-60 [16000571.001]

[Cites] J Biol Chem. 2000 Oct 20;275(42):32775-82 [10922363.001]

[Cites] Dis Colon Rectum. 2006 Aug;49(8):1184-92 [16752205.001]

[Cites] Biochem Biophys Res Commun. 2003 Jun 27;306(2):577-81 [12804604.001]

[Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]

[Cites] Lab Invest. 2005 Feb;85(2):225-36 [15531909.001]

[Cites] Int J Cancer. 2003 Nov 20;107(4):551-6 [14520691.001]

[Cites] Cancer Res. 2008 May 1;68(9):3251-9 [18451151.001]

[Cites] J Biol Chem. 2003 May 23;278(21):19396-405 [12626523.001]

[Cites] Gastroenterology. 2003 Aug;125(2):404-12 [12891542.001]

[Cites] J Pathol. 2006 Feb;208(3):356-63 [16353170.001]

[Cites] Clin Cancer Res. 2001 Dec;7(12 ):3971-6 [11751489.001]

[Cites] J Clin Invest. 2006 May;116(5):1391-9 [16614756.001]

[Cites] J Biol Chem. 2002 Aug 16;277(33):30253-63 [12050152.001]

[Cites] Mol Cancer. 2006 Nov 16;5:62 [17107625.001]

[Cites] Hum Pathol. 2004 Apr;35(4):488-95 [15116331.001]

(PMID = 19412621.001).

[ISSN] 1432-2307

[Journal-full-title] Virchows Archiv : an international journal of pathology

[ISO-abbreviation] Virchows Arch.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / RNA, Messenger; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / PTGES protein, human; EC 5.3.99.3 / PTGES2 protein, human; EC 5.3.99.3 / Prostaglandin-E Synthases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: Tissue samples of primary tumors and metastatic lymph nodes from 150 patients undergoing intentionally curative surgical resections for colorectal adenocarcinoma were immunohistochemically examined for vascular endothelial growth factor-C, cyclooxygenase-2, and CD34 expressions.

A significant correlation was found between the expression scores of vascular endothelial growth factor-C and cyclooxygenase-2 (P < 0.0001), and both also were correlated to microvessels density and several clinicopathologic parameters, including primary tumor size, lymph node metastasis, lymphatic invasion, and TNM stage.

[MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Cyclooxygenase 2 / metabolism. Lymph Nodes / metabolism. Membrane Proteins / metabolism. Vascular Endothelial Growth Factor C / metabolism

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16474989.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD34; 0 / Membrane Proteins; 0 / Vascular Endothelial Growth Factor C; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The clinical significance of fat clearance lymph node harvest for invasive rectal adenocarcinoma following neoadjuvant therapy.

N1 and N2 stages were regarded as N+ stage.

In the nonneoadjuvant group, there was no significant difference in the number of positive lymph nodes (0.5 +/- 0.2 vs. 1.0 +/- 0.3, P = 0.235), N stage (P = 0.265), or patients with N+ stage (7/31 vs. 16/49, P = 0.332) between the two methods, even though the total lymph node harvest was significantly increased by use of the fat clearance method (9.6 +/- 1.3 vs. 27.6 +/- 2.5, P < 0.001).

In contrast, the total lymph node retrieval (5.2 +/- 0.6 vs. 20.4 +/- 1.2, P < 0.001), number of positive lymph nodes (0.4 +/- 0.2 vs. 1.2 +/- 0.3, P = 0.007), N stage (P = 0.005), and patients with N+ stage (6/51 vs. 34/106, P = 0.006) were all increased by fat clearance in the neoadjuvant group.

Moreover, the number of patients with N+ stage was stratified by T stage level (T0-T4) to eliminate the background bias, and the results were confirmed.

[MeSH-major] Adenocarcinoma / pathology. Lymph Node Excision / methods. Rectal Neoplasms / pathology

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19966611.001).

[ISSN] 1530-0358

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Microarray analysis on pooled samples has previously identified ZDHHC9 (DHHC9) to be upregulated in colon adenocarcinoma compared to normal colon mucosa.

Immunohistochemical analysis was performed on 60 colon adenocarcinomas, previously analysed on microarrays, as well as on tissue microarrays with 40 stage I-IV tumours and 46 tumours from different organ sites.

In conclusion, DHHC9 is a gastrointestinal-related protein highly expressed in MSS colon tumours.

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Med Chem. 1997 Sep 12;40(19):2971-90 [9301658.001]

[Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]

[Cites] Cell. 1999 Jul 9;98(1):69-80 [10412982.001]

[Cites] Neuron. 2004 Dec 16;44(6):987-96 [15603741.001]

[Cites] Gut. 2005 Mar;54(3):374-84 [15710986.001]

[Cites] Science. 2005 Mar 18;307(5716):1746-52 [15705808.001]

[Cites] Br J Cancer. 2005 Jun 20;92(12):2240-8 [15956967.001]

[Cites] J Biol Chem. 2005 Sep 2;280(35):31141-8 [16000296.001]

[Cites] Clin Cancer Res. 2005 Dec 1;11(23):8332-40 [16322293.001]

[Cites] Int J Cancer. 2006 Mar 1;118(5):1309-15 [16152604.001]

[Cites] Cancer Res. 2006 Feb 15;66(4):1974-81 [16488996.001]

[Cites] Carcinogenesis. 2006 Mar;27(3):419-28 [16272173.001]

[Cites] J Mol Diagn. 2006 May;8(2):193-201 [16645205.001]

[Cites] World J Gastroenterol. 2006 Aug 7;12(29):4636-9 [16937431.001]

[Cites] Carcinogenesis. 2007 Jan;28(1):38-48 [16774939.001]

[Cites] Mol Cell Biol. 2000 Apr;20(7):2475-87 [10713171.001]

[Cites] Oncol Rep. 2001 Nov-Dec;8(6):1409-13 [11605075.001]

[Cites] Cancer Res. 2002 Aug 1;62(15):4352-63 [12154040.001]

[Cites] Sci STKE. 2002 Oct 1;2002(152):pe41 [12359913.001]

[Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]

[Cites] Gastroenterology. 2002 Dec;123(6):1804-11 [12454837.001]

[Cites] Nat Genet. 2003 Jan;33(1):90-6 [12469123.001]

[Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]

[Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]

[Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]

[Cites] J Biol Chem. 2003 Dec 19;278(51):51957-67 [14522980.001]

[Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]

[Cites] Fam Cancer. 2004;3(2):85-91 [15340258.001]

[Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]

[Cites] J Biol Chem. 1996 May 10;271(19):11541-7 [8626715.001]

[Cites] Biochem Pharmacol. 1998 Dec 1;56(11):1411-26 [9827573.001]

(PMID = 17519897.001).

[ISSN] 0007-0920

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Neoplasm; EC 2.3.- / Acyltransferases; EC 2.3.1.- / ZDHHC9 protein, human

[Other-IDs] NLM/ PMC2359975

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Distribution of a single nucleotide polymorphism of insulin-like growth factor-1 in colorectal cancer patients and its association with mucinous adenocarcinoma.

RESULTS: Young CRC patients had a higher frequency of advanced disease (58.7%) and mucinous adenocarcinoma (20%) than old CRC patients.

Other clinicopathological factors including tumor location, differentiation, lymphovascular invasion, and TNM stage were not associated with the AA genotype of IGF-1.

CONCLUSIONS: Older patients had a higher frequency of the AA genotype of IGF-1(-2995 C/A), while younger patients more often had advanced disease and mucinous adenocarcinoma.

[MeSH-major] Adenocarcinoma, Mucinous / genetics. Colorectal Neoplasms / genetics. Insulin-Like Growth Factor I / genetics. Polymorphism, Single Nucleotide

Genetic Alliance. consumer health - Colorectal Cancer.

Genetic Alliance. consumer health - Colorectal cancer 1.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21161940.001).

[ISSN] 1724-6008

[Journal-full-title] The International journal of biological markers

[ISO-abbreviation] Int. J. Biol. Markers

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Pathological examination determined International Federation of Gynecology and Obstetrics (FIGO) stage IIIc MMMT of the right fallopian tube.

Of note, multiple tumoral nodules were attached to the sigmoid colon.

The tumor attached to the sigmoid colon had shrunk by 60% after chemotherapy.

[MeSH-minor] Adenocarcinoma / pathology. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Ovariectomy

Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.

Hazardous Substances Data Bank. TAXOL .

Hazardous Substances Data Bank. CARBOPLATIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Gynecol Oncol. 1992 Oct;47(1):114-24 [1330846.001]

[Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):101-5 [16445618.001]

[Cites] Int J Gynecol Pathol. 1990;9(1):1-19 [2152890.001]

[Cites] Gynecol Oncol. 2005 Apr;97(1):219-22 [15790462.001]

[Cites] Arch Gynecol Obstet. 1996;258(1):47-53 [8789433.001]

[Cites] Int J Gynecol Cancer. 2004 Jul-Aug;14(4):690-3 [15304169.001]

[Cites] Cancer. 1993 Jan 1;71(1):187-92 [8380115.001]

[Cites] Gynecol Oncol. 1984 Jul;18(3):278-92 [6086467.001]

[Cites] Acta Obstet Gynecol Scand. 1994 Apr;73(4):352-4 [8160547.001]

[Cites] Int J Gynecol Cancer. 1999 Jul;9(4):312-316 [11240785.001]

[Cites] Obstet Gynecol. 1995 May;85(5 Pt 1):735-9 [7724104.001]

(PMID = 18946759.001).

[ISSN] 1341-9625

[Journal-full-title] International journal of clinical oncology

[ISO-abbreviation] Int. J. Clin. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In this study comparing normal colon to colorectal cancer by proteomics, hnRNP K was identified as being overexpressed in this type of cancer.

In normal colon hnRNP K was exclusively nuclear whereas in colorectal cancer the protein localised both in the cytoplasm and the nucleus.

There were significant increases in both nuclear (P=0.007) and cytoplasmic (P=0.001) expression of hnRNP K in Dukes C tumours compared with early stage tumours.

[MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Ribonucleoproteins / biosynthesis

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] EMBO J. 1994 Mar 15;13(6):1476-81 [8137829.001]

[Cites] Br J Cancer. 2003 Oct 20;89(8):1493-501 [14562022.001]

[Cites] J Histochem Cytochem. 1999 Nov;47(11):1457-64 [10544218.001]

[Cites] Genetics. 2000 Dec;156(4):1765-76 [11102372.001]

[Cites] Nat Cell Biol. 2001 Mar;3(3):325-30 [11231586.001]

[Cites] J Biol Chem. 2001 Mar 30;276(13):9699-704 [11121407.001]

[Cites] J Biol Chem. 2002 May 10;277(19):16614-23 [11867641.001]

[Cites] Nucleic Acids Res. 2003 Mar 1;31(5):1502-13 [12595559.001]

[Cites] Lung Cancer. 2003 Aug;41(2):131-43 [12871776.001]

[Cites] Lung Cancer. 2003 Aug;41(2):179-86 [12871781.001]

[Cites] Oncogene. 2003 Sep 11;22(39):8012-20 [12970749.001]

[Cites] Biochim Biophys Acta. 2006 Apr;1765(2):85-100 [16378690.001]

[Cites] Br J Cancer. 2004 May 17;90(10):1955-60 [15138477.001]

[Cites] Cell. 2004 May 28;117(5):649-62 [15163412.001]

[Cites] Bioessays. 2004 Jun;26(6):629-38 [15170860.001]

[Cites] Proc Natl Acad Sci U S A. 1984 Dec;81(23):7471-5 [6594697.001]

[Cites] J Biol Chem. 1993 Aug 25;268(24):18249-58 [8349701.001]

[Cites] J Mol Biol. 1994 Feb 11;236(1):33-48 [8107114.001]

[Cites] FEBS Lett. 1997 Feb 17;403(2):113-5 [9042948.001]

[Cites] Mol Cell Biol. 1999 Nov;19(11):7846-56 [10523673.001]

[Cites] J Pathol. 2005 Jan;205(1):74-81 [15532096.001]

[Cites] J Cell Biochem. 2005 Aug 1;95(5):1042-56 [15962305.001]

[Cites] Cell. 2005 Dec 16;123(6):1065-78 [16360036.001]

[CommentIn] Br J Cancer. 2007 Aug 20;97(4):574-5; author reply 576 [17667925.001]

(PMID = 16953238.001).

[ISSN] 0007-0920

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ribonucleoproteins; 146410-60-8 / HNRNPK protein, human

[Other-IDs] NLM/ PMC2360539

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer.

Nuclear beta-catenin and CD133 are linked with two hallmarks of colon cancer, wingless-type mouse mammary tumour virus integration site (WNT)-pathway dysregulation and colon cancer stem cells (Co-CSCs), respectively.

Herein, we investigated the expression of these markers on serial sections of 162 stage IIA colonic adenocarcinomas.

Moreover, we show that their combined evaluation can identify colon cancer cases with vastly reduced survival (hazard ratio (HR) 13.4, 95% confidence interval (CI): 4.7-38.2) and a high risk of tumour progression (HR 6.8, 95%CI: 3.1-15.0).

In conclusion, the independence of these markers may on the one hand have implications for their presumed value to identify Co-CSCs; on the other hand it allows their combined analysis to become a powerful tool to identify high risk cases of stage IIA colon cancer.

[MeSH-major] Adenocarcinoma / metabolism. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Glycoproteins / analysis. Peptides / analysis. beta Catenin / analysis

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19403300.001).

[ISSN] 1879-0852

[Journal-full-title] European journal of cancer (Oxford, England : 1990)

[ISO-abbreviation] Eur. J. Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides; 0 / beta Catenin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Because recurrent adenocarcinoma of the colon and rectum (CRC) can still be treated with acceptable 5-year survival rates, tumor surveillance plays an important role.

Only in cases where early stage CRC was been completely resected no schematic surveillance must take place.

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - After Surgery.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18622956.001).

[ISSN] 0040-5930

[Journal-full-title] Therapeutische Umschau. Revue thérapeutique

[ISO-abbreviation] Ther Umsch

[Language] ger

[Publication-type] English Abstract; Journal Article

[Publication-country] Switzerland

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Management and prognosis of colon cancer in patients with intestinal obstruction or peritonitis: a French population-based study.

BACKGROUND: In spite of recent advances in our knowledge of tumor biology and therapy, the management and prognosis of patients with colon cancer (CC) revealed by intestinal obstruction or peritonitis (IOP) are not well defined.

The primary independent negative prognostic factor in multivariate analysis was the presence of nodal or distant metastases (Dukes' stage D, p=0.0001), followed by lack of chemotherapy (p=0.008), initial treatment in non-specialized hospitals (p=0.01), onset with IOP (p=0.02), low-volume surgeons (p=0.02).

[MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy. Intestinal Obstruction / etiology. Peritonitis / etiology

MedlinePlus Health Information. consumer health - Intestinal Obstruction.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15917717.001).

[ISSN] 1234-1010

[Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research

[ISO-abbreviation] Med. Sci. Monit.

[Language] eng

[Publication-type] Journal Article; Multicenter Study

[Publication-country] Poland

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Asymptomatic ileal adenocarcinoma in the setting of undiagnosed Crohn's disease.

Examination of the colon was normal.

The biopsy of the ileal mass was consistent with an adenocarcinoma arising from the terminal ileum.

Findings were consistent with ileal adenocarcinoma in the setting of Crohn's disease.

The pathology was stage 1 adenocarcinoma.

This is a unique case in that on a screening colonoscopy, a favorable ileal adenocarcinoma was discovered in the setting of asymptomatic, undiagnosed ileal Crohn's disease in a patient whose father had Crohn's disease diagnosed postmortem.

[MeSH-major] Adenocarcinoma / diagnosis. Crohn Disease / diagnosis. Ileal Neoplasms / diagnosis

Genetic Alliance. consumer health - Crohn Disease.

MedlinePlus Health Information. consumer health - Crohn's Disease.

MedlinePlus Health Information. consumer health - Intestinal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 1983 Mar 1;51(5):878-81 [6821853.001]

[Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]

[Cites] J Clin Gastroenterol. 1984 Jun;6(3):217-24 [6327804.001]

[Cites] World J Surg. 1985 Dec;9(6):914-20 [4082613.001]

[Cites] Cancer. 1989 Jan 15;63(2):360-3 [2910443.001]

[Cites] Surg Gynecol Obstet. 1991 Nov;173(5):343-9 [1948581.001]

[Cites] Dig Dis Sci. 1992 Aug;37(8):1179-84 [1499440.001]

[Cites] Gastroenterology. 1992 Nov;103(5):1444-51 [1358741.001]

[Cites] J Gastroenterol Hepatol. 1999 Nov;14(11):1132-4 [10574144.001]

[Cites] Clin Imaging. 1999 Sep-Oct;23(5):298-301 [10665347.001]

[Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]

[Cites] Scand J Gastroenterol. 2001 Jun;36(6):641-6 [11424324.001]

[Cites] Eur J Gastroenterol Hepatol. 2002 Jul;14(7):805-10 [12169995.001]

[Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]

[Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]

[Cites] Australas Radiol. 2003 Dec;47(4):450-2 [14641202.001]

[Cites] Endoscopy. 2003 Dec;35(12):1009-14 [14648412.001]

[Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):106-16 [14716243.001]

[Cites] Aliment Pharmacol Ther. 2004 Feb 1;19(3):287-93 [14984375.001]

[Cites] Inflamm Bowel Dis. 2004 Jan;10(1):32-5 [15058524.001]

[Cites] Dis Colon Rectum. 2004 May;47(5):778-81 [15037927.001]

[Cites] Radiographics. 2004 May-Jun;24(3):689-702 [15143222.001]

[Cites] Inflamm Bowel Dis. 2004 Feb;10 Suppl 1:S32-4 [15168828.001]

[Cites] Clin Gastroenterol Hepatol. 2004 Jun;2(6):491-7 [15181618.001]

[Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]

[Cites] World J Gastroenterol. 2004 Sep 1;10(17):2585-7 [15300912.001]

[Cites] Gastroenterol Nurs. 2004 Jul-Aug;27(4):170-5 [15326402.001]

[Cites] Lancet. 1973 Jan 6;1(7793):24-6 [4118541.001]

[Cites] Gut. 1973 Feb;14(2):120-4 [4696534.001]

[Cites] Am J Dig Dis. 1973 Dec;18(12):1095-8 [4761532.001]

[Cites] Ann Surg. 1974 Aug;180(2):175-9 [4843046.001]

[Cites] Cancer. 1976 Jun;37(6):2948-59 [949714.001]

[Cites] Am J Surg. 1980 Sep;140(3):396-9 [7425215.001]

[Cites] Gut. 1982 Mar;23(3):188-93 [7040175.001]

[Cites] Dis Colon Rectum. 1993 Jul;36(7):654-61 [8348849.001]

[Cites] Gastroenterology. 1993 Dec;105(6):1716-23 [8253348.001]

[Cites] Med Clin North Am. 1994 Nov;78(6):1399-412 [7967916.001]

[Cites] Gut. 1994 Nov;35(11):1507-8 [7828962.001]

[Cites] Am J Gastroenterol. 1996 Mar;91(3):434-40 [8633487.001]

[Cites] Dis Colon Rectum. 1996 Nov;39(11):1315-21 [8918446.001]

[Cites] Am J Surg. 1997 Mar;173(3):237-9 [9124635.001]

[Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]

[Cites] Am J Surg Pathol. 1998 Mar;22(3):275-84 [9500769.001]

[Cites] Eur J Gastroenterol Hepatol. 1998 May;10(5):431-2 [9619392.001]

[Cites] Surgery. 1956 Feb;39(2):347-51 [13298987.001]

[Cites] Gastroenterology. 2006 Apr;130(4):1039-46 [16618397.001]

[Cites] Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:1-5 [12950413.001]

(PMID = 18698685.001).

[ISSN] 1007-9327

[Journal-full-title] World journal of gastroenterology

[ISO-abbreviation] World J. Gastroenterol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] China

[Other-IDs] NLM/ PMC2738795

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHOD: Prospective registration of all operated patients as well as inclusions (curative resection, stage II or III disease, <or= 75 years, clean colon and exclusions of the individual patients in eight participating departments.

[MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Patient Selection. Rectal Neoplasms / surgery

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19708095.001).

[ISSN] 1463-1318

[Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

[ISO-abbreviation] Colorectal Dis

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

SUMMARY BACKGROUND DATA: The incidence of rectal cancer increases with older age, and localized disease can be curatively treated with stage-appropriate radical surgery.

METHODS: Patients with localized rectal adenocarcinoma were identified in the Surveillance, Epidemiology, and End Results database (1991-2002).

Each half-decade increase in age > or =70 years was associated with a 37% increase in the relative risk (RR) for cancer-related mortality (RR = 1.37; 95% confidence interval [CI], 1.33-1.42); decreased receipt of cancer-directed surgery (odds ratio [OR] = 0.56; 95% CI, 0.36-0.63); more local excision and less radical surgery (OR = 0.76; 95% CI, 0.72-0.81); less radiotherapy (OR = 0.64; 95% CI, 0.61-0.67); and greater likelihood of N0 pathologic stage classification (OR = 1.10; 95% CI, 1.05-1.15) (P < 0.0001 for each factor).

[MeSH-major] Adenocarcinoma / epidemiology. Rectal Neoplasms / epidemiology

Genetic Alliance. consumer health - Rectal Cancer.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Surg. 2000 Mar;231(3):345-51 [10714627.001]

[Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]

[Cites] Crit Rev Oncol Hematol. 2000 Sep;35(3):161-79 [10960799.001]

[Cites] Lancet. 2000 Sep 16;356(9234):968-74 [11041397.001]

[Cites] Dis Colon Rectum. 2000 Dec;43(12):1704-9 [11156454.001]

[Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]

[Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]

[Cites] Eur J Surg Oncol. 2002 Sep;28(6):661-6 [12359205.001]

[Cites] Ann Surg. 2002 Oct;236(4):522-29; discussion 529-30 [12368681.001]

[Cites] Am J Surg. 2003 Jan;185(1):54-7 [12531446.001]

[Cites] Crit Rev Oncol Hematol. 2003 Nov;48(2):159-63 [14607379.001]

[Cites] Clin Colorectal Cancer. 2003 Nov;3(3):165-71 [14706175.001]

[Cites] Strahlenther Onkol. 2004 Aug;180(8):478-87 [15292968.001]

[Cites] Br J Surg. 2004 Oct;91(10):1345-51 [15376202.001]

[Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]

[Cites] Ann Surg Oncol. 2004 Nov;11(11):962-9 [15525824.001]

[Cites] Surg Oncol. 2004 Dec;13(4):223-34 [15615660.001]

[Cites] Br J Surg. 2005 May;92(5):615-23 [15779071.001]

[Cites] J Clin Oncol. 2005 Jun 1;23(16):3802-10 [15923574.001]

[Cites] J Natl Compr Canc Netw. 2005 Jul;3(4):492-508 [16038640.001]

[Cites] Dis Colon Rectum. 2005 Sep;48(9):1755-63 [15981072.001]

[Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]

(PMID = 17667499.001).

[ISSN] 0003-4932

[Journal-full-title] Annals of surgery

[ISO-abbreviation] Ann. Surg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC1933551

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: We present a case of recurrent colon cancer detected by routine, annual Papanicolaou screening.

CASE: A 59-year-old African American woman who had been treated for T2N0M0 (stage II, Dukes A) colon cancer 2 years before to presentation had a Pap smear showing a high-grade squamous intraepithelial lesion with a normal cervical biopsy result.

Because of this discrepancy, a loop electrosurgical excision procedure and endocervical curettage were performed and showed atypical glandular cells suspicious for adenocarcinoma.

Subsequent colonoscopy showed recurrent adenocarcinoma of the colon.

The patient underwent an en-block total abdominal hysterectomy and anterior-perineal resection showing invasion of recurrent colon cancer into the uterus and cervix.

CONCLUSION: In patients with a history of extrauterine adenocarcinoma, abnormal Pap screening may indicate recurrent or metastatic carcinoma.

[MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Diagnostic Tests, Routine. Neoplasm Recurrence, Local / diagnosis. Papanicolaou Test. Uterine Neoplasms / diagnosis. Vaginal Smears

MedlinePlus Health Information. consumer health - Cervical Cancer Screening.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Health Screening.

MedlinePlus Health Information. consumer health - Uterine Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16205196.001).

[ISSN] 1089-2591

[Journal-full-title] Journal of lower genital tract disease

[ISO-abbreviation] J Low Genit Tract Dis

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: To evaluate survival and prognostic factors in a consecutive series of colon cancer patients from a defined city population in Norway.

METHOD: All patients with adenocarcinoma of the colon diagnosed between 1993 and 2000 were registered prospectively.

Tumour location in the transverse colon, splenic flexure and descending colon (OR = 1.8), emergency operation (OR = 1.7), TNM stage (OR = 1.8-2.9), blood transfusion of more than two units (OR = 1.8) and age (OR = 4.0-7.1) were independent negative prognostic factors.

CONCLUSION: Colon cancer located in the transverse and descending colon is associated with poor prognosis.

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Neoplasm Recurrence, Local / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17672872.001).

[ISSN] 1463-1318

[Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

[ISO-abbreviation] Colorectal Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.

PATIENTS AND METHODS: We analyzed data from Intergroup trial 0089 of adjuvant chemotherapy for stage II and III patients with colon cancer, in which all patients received fluorouracil-based therapy.

Covariates included in the models were age, sex, tumor stage, grade, histology, number of positive LNs, number of LNs removed, and LNR.

[MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / therapy. Lymphatic Metastasis / pathology

Genetic Alliance. consumer health - Metastatic cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16314630.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.

Two recent North American studies have shown that completion of 5-fluorouracil (5FU)-based adjuvant chemotherapy is a major prognostic factor for the survival of elderly stage III colon cancer patients.

The study cohort comprised 851 stage III colon cancer patients treated by surgery alone and 461 who initiated the Mayo chemotherapy regime.

The current and previous studies demonstrate the importance of completing adjuvant 5-FU-based chemotherapy for colon cancer.

[MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / drug therapy. Colonic Neoplasms / mortality

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. FLUOROURACIL .

Hazardous Substances Data Bank. LEUCOVORIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2002 Sep 1;20(17):3605-16 [12202661.001]

[Cites] J Clin Oncol. 2002 Mar 15;20(6):1491-8 [11896096.001]

[Cites] J Clin Oncol. 2002 Oct 1;20(19):3992-8 [12351596.001]

[Cites] Br J Cancer. 2003 May 19;88(10):1510-5 [12771914.001]

[Cites] Br J Cancer. 2003 Jun 16;88(12):1859-65 [12799627.001]

[Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]

[Cites] Clin Cancer Res. 2003 Aug 1;9(8):2898-903 [12912934.001]

[Cites] J Clin Oncol. 2003 Oct 15;21(20):3729-36 [14551292.001]

[Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5860-5 [14676107.001]

[Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]

[Cites] Oncology (Williston Park). 2004 May;18(6):751-5; discussion 755-8 [15214594.001]

[Cites] Eur J Cancer. 2004 Oct;40(15):2230-6 [15454247.001]

[Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]

[Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]

[Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]

[Cites] J Clin Oncol. 1992 Jul;10(7):1171-5 [1607921.001]

[Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]

[Cites] J Clin Oncol. 1994 Jun;12(6):1291-5 [8201391.001]

[Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]

[Cites] J Clin Oncol. 1998 Nov;16(11):3537-41 [9817272.001]

[Cites] Eur J Cancer. 1998 Nov;34(12):1871-5 [10023308.001]

[Cites] Cancer. 2005 Mar 15;103(6):1165-71 [15693031.001]

[Cites] J Clin Oncol. 2005 Mar 20;23(9):1819-25 [15774775.001]

[Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]

[Cites] N Engl J Med. 2005 Jun 30;352(26):2746-8 [15987925.001]

[Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]

[Cites] Dig Surg. 2005;22(6):401-14 [16479107.001]

[Cites] J Natl Cancer Inst. 2006 May 3;98(9):610-9 [16670386.001]

[Cites] J Clin Oncol. 2006 May 20;24(15):2368-75 [16618946.001]

[Cites] J Clin Oncol. 2007 Jan 1;25(1):102-9 [17194911.001]

[Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]

[Cites] Br J Cancer. 2001 Mar 2;84(5):600-3 [11237378.001]

[Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]

[Cites] J Clin Oncol. 2002 Sep 1;20(17):3617-27 [12202662.001]

(PMID = 17299387.001).

[ISSN] 0007-0920

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil

[Other-IDs] NLM/ PMC2360063

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

All underwent transhiatal esophagectomy and gastric tube or colon was used as the conduit to restore continuity.

The TNM staging were stage I, IIa, IIb, III and IV in zero (0), 5 (11%), 10 (22%), 24 (57.8%) and 3 (7.1%) respectively.

The frequency of complications is lower as compared to transthoracic approach and the early stage of presentation can lead to high 5-year survival ratios.

[MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods

MedlinePlus Health Information. consumer health - Esophageal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19576147.001).

[ISSN] 1022-386X

[Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

[ISO-abbreviation] J Coll Physicians Surg Pak

[Language] eng

[Publication-type] Journal Article

[Publication-country] Pakistan

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Two-port hand-assisted laparoscopic surgery for the 2-stage treatment of a complete bowel obstruction by left colon cancer: a case report.

Since a bowel obstruction by left colon cancer was suspected due to a marked dilation of the transverse colon, she was referred to our hospital.

On admission, an enema disclosed a complete obstruction at the splenic flexure of the colon.

An emergency operation was performed, and a temporary loop colostomy was fashioned on the left side of the transverse colon within the range of resection for 2-stage radical surgery.

The histological diagnosis was Type 2 circumferential well-differentiated adenocarcinoma with local peritoneal dissemination.

Our experience suggests that 2-stage surgery combined with 2P-HALS is applicable even to a large obstructing left colon cancer.

MedlinePlus Health Information. consumer health - Intestinal Obstruction.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18357370.001).

[ISSN] 1021-335X

[Journal-full-title] Oncology reports

[ISO-abbreviation] Oncol. Rep.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Greece

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Only stage correlated with positive CTCs (20.7% in stage II, 24.1% in stage III and 60.7% in stage IV, P = 0.005).

CONCLUSIONS: CTCs detection by CellSearch is a highly reproducible method that correlates with stage but not with other clinical and morphological variables in patients with colorectal cancer.

Colon cancer tumor cells are detectable in all stages.

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18212090.001).

[ISSN] 1569-8041

[Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology

[ISO-abbreviation] Ann. Oncol.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; EC 1.1.1.27 / L-Lactate Dehydrogenase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary solid tumors of the colon and rectum in the pediatric patient: a review of 270 cases.

OBJECTIVE: To study the outcomes of solid tumors of the colon and rectum in pediatric patients.

Tumors were identified in the right colon (45.9%), transverse colon (9.3%), left colon (20.4%), rectum (15.2%), and anal canal (1.1%).

The most common histology of these tumors was adenocarcinoma (35.6%), followed by carcinoid (34.1%).

Multivariate analysis of the cohort identified tumor stage (HR 8.39, P < 0.001 for distant disease), tumor type (signet ring HR 2.12, P = 0.025, and carcinoid HR = 0.14, P = 0.001), and surgical resection (no surgery HR 2.98, P = 0.010) as independent predictors of worse outcome.

CONCLUSION: In the pediatric population, solid tumors of the colon and rectum occur more frequently in the right side of the colon in teenagers.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 Elsevier Inc. All rights reserved.

(PMID = 19285688.001).

[ISSN] 1095-8673

[Journal-full-title] The Journal of surgical research

[ISO-abbreviation] J. Surg. Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: This prospective study from the Norwegian Rectal Cancer Project includes all 2,283 patients younger than aged 70 years with adenocarcinoma of the rectum from November 1993 to December 1999.

RESULTS: Patients younger than aged 40 years had significantly higher frequencies of poorly differentiated tumors (27 vs. 12-16 percent; P = 0.014), N2-stage (37 vs. 13-18 percent; P = 0.001), and distant metastases (38 vs. 19-24 percent; P = 0.019) compared with older patients.

CONCLUSIONS: Patients younger than aged 40 years had a more advanced stage at the time of diagnosis and poor prognosis compared with older patients.

[MeSH-major] Adenocarcinoma / therapy. Rectal Neoplasms / therapy

Genetic Alliance. consumer health - Rectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16741599.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.

BACKGROUND: Loss of CD95 expression in tumour cells occurs frequently in colon carcinoma and may be associated with disease progression.

AIMS: We aimed at further exploring the functional role and prognostic significance of the CD95/CD95L death inducing system in colon carcinomas.

PATIENTS AND METHODS: CD95 and CD95L expression was examined by immunohistochemistry in 128 R0 resected UICC (International Union against Cancer) stage II/III colon carcinomas and correlated with disease free survival.

Tumour infiltrating lymphocytes (TIL) were the major source of CD95L in colon carcinomas.

Moreover, a high rate of CD95L+TIL correlated with prolonged disease free survival in patients with UICC stage II (p = 0.05) but not in those with stage III.

CONCLUSIONS: Loss of CD95 in tumour cells may be an independent prognostic factor in colon carcinomas.

The CD95L counterattack is not a relevant feature in colon carcinoma but CD95L+TIL may contribute to tumour control in the early stages of the disease, exerting a concurrent selection pressure in the direction of CD95 abrogation/resistance.

[MeSH-major] Adenocarcinoma / immunology. Antigens, CD95 / metabolism. Biomarkers, Tumor / metabolism. Colonic Neoplasms / immunology. Membrane Glycoproteins / metabolism

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Hum Pathol. 1999 Nov;30(11):1309-13 [10571510.001]

[Cites] Cell Death Differ. 2001 Mar;8(3):273-8 [11319610.001]

[Cites] J Immunol. 2000 May 15;164(10):5023-7 [10799856.001]

[Cites] J Pathol. 2001 May;194(1):15-9 [11329136.001]

[Cites] J Immunol. 2001 Aug 15;167(4):2068-73 [11489989.001]

[Cites] Cancer Cell. 2002 Aug;2(2):139-48 [12204534.001]

[Cites] J Immunol. 2003 Jun 15;170(12):5973-80 [12794124.001]

[Cites] Gastroenterology. 2003 Sep;125(3):708-15 [12949717.001]

[Cites] J Immunol. 2003 Oct 15;171(8):4164-74 [14530339.001]

[Cites] Cancer. 1981 Mar 1;47(5):930-6 [7226044.001]

[Cites] Cell. 1991 Jul 26;66(2):233-43 [1713127.001]

[Cites] J Biol Chem. 1992 May 25;267(15):10709-15 [1375228.001]

[Cites] Lab Invest. 1993 Oct;69(4):415-29 [7693996.001]

[Cites] Int J Cancer. 1994 May 1;57(3):371-7 [8168998.001]

[Cites] Int J Cancer. 1996 Sep 4;67(5):709-14 [8782663.001]

[Cites] Science. 1996 Nov 22;274(5291):1363-6 [8910274.001]

[Cites] J Exp Med. 1996 Sep 1;184(3):1075-82 [9064324.001]

[Cites] J Exp Med. 1996 Sep 1;184(3):1149-54 [9064331.001]

[Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]

[Cites] Gastroenterology. 1997 Jul;113(1):160-7 [9207274.001]

[Cites] Cancer Res. 1998 Feb 1;58(3):526-34 [9458101.001]

[Cites] Cancer Res. 1998 Aug 15;58(16):3491-4 [9721846.001]

[Cites] J Exp Med. 1998 Nov 2;188(9):1717-23 [9802983.001]

[Cites] J Pathol. 1998 Nov;186(3):240-6 [10211111.001]

[Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]

[Cites] J Exp Med. 1999 Oct 4;190(7):1033-8 [10510093.001]

[Cites] J Immunol. 2000 May 1;164(9):4941-54 [10779805.001]

(PMID = 15831912.001).

[ISSN] 0017-5749

[Journal-full-title] Gut

[ISO-abbreviation] Gut

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, CD95; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Ligands; 0 / Membrane Glycoproteins

[Other-IDs] NLM/ PMC1774512

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Adjuvant chemotherapy for colon cancer].

BACKGROUND: Radical resection is the main treatment for adenocarcinoma of the colon.

The background for adjuvant chemotherapy of colon cancer is presented.

RESULTS AND INTERPRETATION: Cure rates after curative resections of colon cancer (stage III) are improved by about 12% if patients are treated with adjuvant chemotherapy with oxaliplatin combined with 5-fluoruracil and folinat (or capecitabine) for 6 months.

Certain subgroups of stage II (Dukes' stage B) are also likely to benefit from adjuvant chemotherapy.

[MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18049502.001).

[ISSN] 0807-7096

[Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række

[ISO-abbreviation] Tidsskr. Nor. Laegeforen.

[Language] nor

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Norway

[Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents

[Number-of-references] 35

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Mucinous carcinoma of the colon and rectum in Phramongkutklao Hospital.

OBJECTIVE: The objective of the present study was to compare the clinicopathological significance between mucinous carcinoma and nonmucinous adenocarcinoma.

MATERIAL AND METHOD: Patients with carcinoma of the colon and rectum who had the first operation in the Department of Surgery, Phramongkutklao Hospital between 1999 and 2004 were included in the present study.

There was no difference in sex distribution, location of tumors, depth of invasion, lymph node involvement, distant metastasis, TNM stage, lymphatic invasion, vascular invasion, perineural invasion, peritoneal seeding, curability, positive microscopic margin, and adhesion to the surrounding structure.

CONCLUSION: Colorectal mucinous carcinoma had no clinicopathological difference from nonmucinous adenocarcinoma of colon and rectum.

[MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Colonic Neoplasms / pathology. Rectal Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16583577.001).

[ISSN] 0125-2208

[Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet

[ISO-abbreviation] J Med Assoc Thai

[Language] eng

[Publication-type] Journal Article

[Publication-country] Thailand

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

No significant difference in occurrence of micrometastasis was observed among tumors of different stage.

[MeSH-major] Adenocarcinoma / pathology. Mesentery / pathology. Neoplasm Recurrence, Local / pathology. Rectal Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Br J Surg. 1996 Jun;83(6):781-5 [8696739.001]

[Cites] Br J Surg. 1997 May;84(5):652-6 [9171754.001]

[Cites] Br J Surg. 1995 Aug;82(8):1031-3 [7648142.001]

[Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]

[Cites] Br J Surg. 1984 Jan;71(1):12-6 [6689962.001]

[Cites] Am J Clin Pathol. 1996 Aug;106(2):209-16 [8712176.001]

[Cites] J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44 [1912440.001]

[Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]

[Cites] Lancet. 1990 May 5;335(8697):1055-9 [1691810.001]

[Cites] Br J Surg. 2002 Mar;89(3):327-34 [11872058.001]

[Cites] J Am Coll Surg. 1997 Jun;184(6):584-8 [9179114.001]

[Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]

[Cites] Am J Surg Pathol. 2002 Mar;26(3):350-7 [11859207.001]

[Cites] Cancer. 1995 Aug 1;76(3):388-92 [8625118.001]

[Cites] Br J Hosp Med. 1992 Feb 19-Mar 3;47(4):247-8 [1591538.001]

[Cites] Langenbecks Arch Surg. 1999 Apr;384(2):167-75 [10328170.001]

[Cites] Ann Surg. 2002 Apr;235(4):449-57 [11923599.001]

[Cites] Br J Surg. 1989 Nov;76(11):1165-7 [2688803.001]

[Cites] Br J Surg. 1997 Nov;84(11):1546-50 [9393276.001]

[Cites] Dis Colon Rectum. 1998 Aug;41(8):979-83 [9715152.001]

[Cites] Lancet. 1994 Sep 10;344(8924):707-11 [7915774.001]

[Cites] Dis Colon Rectum. 2003 Jun;46(6):779-85 [12794580.001]

[Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]

(PMID = 16049726.001).

[ISSN] 1435-2443

[Journal-full-title] Langenbeck's archives of surgery

[ISO-abbreviation] Langenbecks Arch Surg

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Adjuvant chemotherapy of oral uracil/ftorafur (UFT) plus leucovorin (LV) has been accepted as the standard of care in the treatment of patients with stage II and III carcinoma of the colon.

CONCLUSIONS: HRQOL in colorectal cancer patients with adjuvant chemotherapy with oral UFT plus LV deteriorated during this phase of treatment compared with those with surgery alone, despite the biased stage of tumor between the groups.

[MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colectomy. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Quality of Life

Genetic Alliance. consumer health - Colorectal Cancer.

Genetic Alliance. consumer health - Oral cancer.

Genetic Alliance. consumer health - Oral Health.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

Hazardous Substances Data Bank. LEUCOVORIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 2000 Mar 15;88(6):1294-303 [10717609.001]

[Cites] Cancer. 1998 Jun 1;82(11):2135-44 [9610692.001]

[Cites] J Clin Oncol. 2006 May 1;24(13):2059-64 [16648506.001]

[Cites] Dis Colon Rectum. 2006 Nov;49(11):1663-72 [17041749.001]

[Cites] J Clin Oncol. 2007 Feb 1;25(4):424-30 [17264338.001]

[Cites] Eur J Cancer. 1998 May;34(6):810-5 [9797690.001]

[Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]

[Cites] J Clin Oncol. 2002 Sep 1;20(17):3605-16 [12202661.001]

[Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]

[Cites] Qual Life Res. 2008 Mar;17(2):317-22 [18095186.001]

[Cites] Br J Cancer. 2007 Apr 23;96(8):1170-7 [17375049.001]

[Cites] Acta Oncol. 2007;46(1):77-82 [17438708.001]

[Cites] J Clin Oncol. 2004 Sep 1;22(17):3466-74 [15277535.001]

[Cites] J Clin Oncol. 2002 Sep 1;20(17):3617-27 [12202662.001]

[Cites] Dis Colon Rectum. 1995 Apr;38(4):361-9 [7720441.001]

(PMID = 20191299.001).

[ISSN] 1437-7772

[Journal-full-title] International journal of clinical oncology

[ISO-abbreviation] Int. J. Clin. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Haematoxylin and Eosin stained slides were examined to determine the histological type, grade and stage of CRC.

RESULTS: Among the 100 cases, 59 were non mucinous adenocarcinomas, of which 4 were in Dukes' stage A, 51 were in Dukes' stage B and 4 were in Dukes' stage C.

In thirty cases of mucinous carcinomas, 18 were in Dukes' stage B and 12 were in Dukes' stage C, of these 2 were of grade I, 20 were of grade II and 8 were of grade III.

All the 11 signet ring cell carcinomas were of grade III and in Dukes' stage C.

CONCLUSION: Mucin secreting and signet-ring cell adenocarcinomas of colon and rectum are high grade tumours and presented at an advanced stage.

[MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Colorectal Neoplasms / classification. Colorectal Neoplasms / pathology. Neoplasm Staging

MedlinePlus Health Information. consumer health - Colorectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21381550.001).

[ISSN] 0030-9982

[Journal-full-title] JPMA. The Journal of the Pakistan Medical Association

[ISO-abbreviation] J Pak Med Assoc

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] Pakistan

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

A T3N0 preoperative tumor stage was found in 21 (75%) patients in the LI group and in 33 (85%) patients in the SI group (p = 0.36).

All tumors were histologically proven adenocarcinoma.

[MeSH-minor] Adenocarcinoma. Age Factors. Aged. Digestive System Surgical Procedures. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Time Factors. Treatment Outcome

Genetic Alliance. consumer health - Rectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Colorectal Dis. 2007 May;22(5):507-13 [17009009.001]

[Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]

[Cites] Ann Surg. 2007 Nov;246(5):693-701 [17968156.001]

[Cites] Colorectal Dis. 2008 Jul;10(6):563-8 [18070184.001]

[Cites] Br J Surg. 1995 Oct;82(10):1297-9 [7489148.001]

[Cites] J Clin Oncol. 2001 Apr 1;19(7):1976-84 [11283130.001]

[Cites] Cancer. 2002 Feb 15;94(4):1121-30 [11920483.001]

[Cites] Int J Colorectal Dis. 2005 Sep;20(5):440-5 [15856263.001]

[Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):752-60 [15936556.001]

[Cites] Hum Pathol. 2003 Jun;34(6):541-8 [12827607.001]

[Cites] Dis Colon Rectum. 2004 Dec;47(12):2025-31 [15657650.001]

[Cites] Colorectal Dis. 2002 May;4(3):177-183 [12780612.001]

[Cites] Cancer Control. 2003 May-Jun;10(3):205-11 [12794618.001]

[Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]

[Cites] Ann Surg Oncol. 2008 Dec;15(12):3471-7 [18846402.001]

[Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]

(PMID = 19415307.001).

[ISSN] 1432-1262

[Journal-full-title] International journal of colorectal disease

[ISO-abbreviation] Int J Colorectal Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

C-reactive protein, albumin and carcinoembryonic antigen are not predictive of cancer site, Duke's stage or influenced by patient age or gender.

[MeSH-major] Adenocarcinoma / pathology. Colonoscopy. Colorectal Neoplasms / pathology. Sigmoidoscopy

[MeSH-minor] Anemia / diagnosis. Anemia / etiology. Colon, Ascending / pathology. Constipation / etiology. Diarrhea / etiology. Humans. Risk Factors

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colonoscopy.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Colorectal Dis. 2010 Aug;12(8):834-5 [20456465.001]

(PMID = 19207710.001).

[ISSN] 1463-1318

[Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

[ISO-abbreviation] Colorectal Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

LNgamma2 expression was seen in 57% of patients with biliary tract cancer, and was associated with depth of invasion, histologic type, and advanced stage.

The invasive front dominant type was associated with histologic type and advanced stage.

Active MMP7 detected by casein zymography was correlated with depth of invasion and advanced stage.

[MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Animals. Cell Line, Tumor. Female. Humans. Male. Middle Aged. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cell. 1991 May 17;65(4):599-610 [2032285.001]

[Cites] Pathol Int. 2004 Sep;54(9):688-92 [15363037.001]

[Cites] Am J Pathol. 1994 Oct;145(4):782-91 [7943170.001]

[Cites] FEBS Lett. 1995 Jul 24;368(3):556-8 [7635220.001]

[Cites] Cancer Res. 1995 Sep 15;55(18):4132-9 [7664291.001]

[Cites] Am J Pathol. 1995 Oct;147(4):1123-32 [7573357.001]

[Cites] J Biochem. 1996 Dec;120(6):1196-202 [9010770.001]

[Cites] Gastroenterology. 1997 Apr;112(4):1290-6 [9098015.001]

[Cites] Science. 1997 Jul 11;277(5323):225-8 [9211848.001]

[Cites] J Pathol. 1998 May;185(1):44-52 [9713359.001]

[Cites] Cancer Res. 1999 Jul 15;59(14):3313-6 [10416584.001]

[Cites] Am J Pathol. 1999 Oct;155(4):1033-8 [10514384.001]

[Cites] Carcinogenesis. 2004 Dec;25(12):2353-60 [15333466.001]

[Cites] Gastroenterology. 2005 Nov;129(5):1375-83 [16285938.001]

[Cites] Oncogene. 2005 Nov 24;24(53):7946-52 [16007117.001]

[Cites] Exp Biol Med (Maywood). 2006 Jan;231(1):20-7 [16380641.001]

[Cites] Cancer Res. 2006 Dec 1;66(23):11228-37 [17145868.001]

[Cites] Crit Rev Oncol Hematol. 2007 Jan;61(1):44-51 [17164111.001]

[Cites] J Pathol. 2007 Apr;211(5):516-23 [17318812.001]

[Cites] J Pathol. 2007 May;212(1):102-11 [17370299.001]

[Cites] Cancer Lett. 2007 Aug 28;254(1):42-53 [17374440.001]

[Cites] Curr Probl Surg. 2007 Jul;44(7):396-482 [17693325.001]

[Cites] J Pathol. 2007 Oct;213(2):131-9 [17724792.001]

[Cites] Cancer Res. 1999 Nov 1;59(21):5596-601 [10554040.001]

[Cites] J Cell Biol. 2000 Feb 7;148(3):615-24 [10662785.001]

[Cites] Am J Pathol. 2001 Mar;158(3):1129-35 [11238061.001]

[Cites] Mol Carcinog. 2001 Feb;30(2):119-29 [11241759.001]

[Cites] Clin Cancer Res. 2001 Apr;7(4):896-900 [11309339.001]

[Cites] Int J Cancer. 2001 Sep 20;95(5):290-4 [11494227.001]

[Cites] Cancer Res. 2001 Nov 15;61(22):8089-93 [11719433.001]

[Cites] Semin Cancer Biol. 2002 Jun;12(3):197-207 [12083850.001]

[Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3684-91 [14506159.001]

[Cites] Clin Chem. 2004 Mar;50(3):490-9 [14726470.001]

[Cites] Dis Colon Rectum. 1993 Jul;36(7):627-35 [8348847.001]

(PMID = 19701966.001).

[ISSN] 2219-2840

[Journal-full-title] World journal of gastroenterology

[ISO-abbreviation] World J. Gastroenterol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / LAMC2 protein, human; 0 / Laminin; 0 / RNA, Small Interfering; 0 / kalinin; 170834-93-2 / laminin alpha 3; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7

[Other-IDs] NLM/ PMC2731248

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The following anal cancer histologies were included in the analysis: squamous cell, adenocarcinoma, and small cell/neuroendocrine carcinomas.

The majority of SCC cases were diagnosed at the in situ or localized stage (58.1%).

API were more likely to be diagnosed with regional or distant stage disease than were other racial/ethnic groups (27.5% and 11.8%, respectively).

A higher proportion of API were diagnosed at regional/distant stage.

MedlinePlus Health Information. consumer health - Anal Cancer.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]

[Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]

[Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]

[Cites] AIDS. 2003 Feb 14;17(3):311-20 [12556684.001]

[Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]

[Cites] Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524 [14605572.001]

[Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]

[Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]

[Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]

[Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]

[Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]

[Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]

[Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]

[Cites] Am J Epidemiol. 1992 Jul 1;136(1):54-8 [1329500.001]

[Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]

[Cites] Am J Epidemiol. 1994 Jul 1;140(1):12-9 [8017399.001]

[Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]

[Cites] Semin Cancer Biol. 1998 Aug;8(4):307-13 [9870037.001]

[Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]

[Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]

[Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]

[Cites] MMWR Morb Mortal Wkly Rep. 2006 Oct 27;55(42):1145-8 [17065979.001]

[Cites] Stat Methods Med Res. 2006 Dec;15(6):547-69 [17260923.001]

[Cites] Lancet Oncol. 2007 Apr;8(4):311-6 [17395104.001]

[Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]

[Cites] Clin Microbiol Rev. 2007 Jul;20(3):478-88, table of contents [17630336.001]

[Cites] Sex Transm Infect. 2007 Jul;83(4):257-66 [17664359.001]

[Cites] Cancer Causes Control. 2007 Dec;18(10):1175-86 [17805982.001]

[Cites] Cancer. 2008 Nov 15;113(10 Suppl):2841-54 [18980203.001]

[Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]

[Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]

(PMID = 18980293.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] ENG

[Grant] None / None / / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04

[Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Other-IDs] NLM/ NIHMS104103; NLM/ PMC2729501

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: KAI1 COOH-terminal interacting tetraspanin (KITENIN) promotes tumor cell migration, invasion and metastasis in colon, bladder, head and neck cancer.

Expression of KITENIN was significantly associated with tumor size, Lauren classification, depth of invasion, lymph node metastasis, tumor stage and poor survival.

[MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carrier Proteins / metabolism. Membrane Proteins / metabolism. Stomach Neoplasms / pathology

MedlinePlus Health Information. consumer health - Stomach Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20944126.001).

[ISSN] 1791-7530

[Journal-full-title] Anticancer research

[ISO-abbreviation] Anticancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Greece

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / Transcription Factor AP-1; 0 / VANGL1 protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Abnormal expression of Endoglin and its receptor complex (TGF-β1 and TGF-β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa.

The simultaneous expression of Endoglin (CD105), transforming growth factor (TGF)-β1 and TGF-β receptor (R) II were quantified in surgical specimens comprising normal human colon, pre-malignant dysplastic tissue, in situ, and invasive colon cancer specimens, at mRNA and protein levels, respectively by real-time PCR and immunohistochemistry.

Serum concentrations of soluble Endoglin and TGF-β1 were evaluated. mRNA and CD105+-microvessel density (MVD) increased significantly in dysplastic colon and carcinoma versus normal tissues; values correlated respectively with dysplasia degree and Dukes' stages.

TGF-β1 RII was overexpressed in adenoma and carcinoma versus normal samples, but unrelated with dysplasia or Dukes' stage.

These findings suggest active angiogenesis occurs in many pre-malignant colon cases and supports more careful evaluation of different chemopreventive agents.

[MeSH-major] Adenocarcinoma / metabolism. Antigens, CD / biosynthesis. Colonic Neoplasms / metabolism. Precancerous Conditions / metabolism. Protein-Serine-Threonine Kinases / biosynthesis. Receptors, Cell Surface / biosynthesis. Receptors, Transforming Growth Factor beta / biosynthesis. Transforming Growth Factor beta1 / biosynthesis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20878063.001).

[ISSN] 1791-2423

[Journal-full-title] International journal of oncology

[ISO-abbreviation] Int. J. Oncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Greece

[Chemical-registry-number] 0 / Antigens, CD; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: From 1995 to 2000, 108 patients with adenocarcinoma of the colon or rectum, underwent curative surgery and enrolled in this prospective study.

The proportion of patients with portal CEA > or =5 ng/ml was greater in patients with higher stage than in patients with lower stage.

[MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Carcinoembryonic Antigen / genetics. Colonic Neoplasms / diagnosis. Rectal Neoplasms / diagnosis

Genetic Alliance. consumer health - Colorectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2006 Wiley-Liss, Inc.

(PMID = 16788936.001).

[ISSN] 0022-4790

[Journal-full-title] Journal of surgical oncology

[ISO-abbreviation] J Surg Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / RNA, Messenger

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Are 12 nodes needed to accurately stage T1 and T2 colon cancers?

Evaluation of 12 lymph nodes has been mandated to prevent colon cancer understaging.

Given that the probability of node metastases is largely associated with T-stage, are <12 nodes substandard for T1 and T2 lesions?

In SEER, 61,237 patients undergoing colon cancer resection were identified.

For each T-stage, 5-year survival rates were compared for node-negative cancers by using stepwise node cut-point comparisons (4 nodes, <4, etc.).

In conclusion, the number of nodes to stage T1 and T2 lesions may be <12.

[MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colonic Neoplasms / pathology. Lymphatic Metastasis / diagnosis. Neoplasm Staging / standards

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Dig Dis Sci. 2009 Apr;54(4):914-5; author reply 916 [19003528.001]

[Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]

[Cites] Colorectal Dis. 2008 Mar;10(3):231-8 [18257848.001]

[Cites] Am J Clin Pathol. 1996 Aug;106(2):209-16 [8712176.001]

[Cites] J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44 [1912440.001]

[Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]

[Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]

[Cites] J Surg Oncol. 2002 Oct;81(2):63-9 [12355405.001]

[Cites] J Clin Oncol. 2001 Jan 1;19(1):157-63 [11134208.001]

[Cites] Arch Pathol Lab Med. 2000 Jul;124(7):958-65 [10888771.001]

[Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]

[Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]

[Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]

[Cites] World J Surg. 2002 Mar;26(3):384-9 [11865379.001]

[Cites] Ann Surg Oncol. 2003 Apr;10(3):213-8 [12679304.001]

[Cites] Cancer. 1999 Jan 1;85(1):243-5 [9922000.001]

[Cites] Bull Am Coll Surg. 2002 Jul;87(7):13-5 [17387902.001]

[Cites] J Surg Oncol. 2008 Apr 1;97(5):383-7 [18163435.001]

[Cites] Dis Colon Rectum. 2002 Feb;45(2):200-6 [11852333.001]

[Cites] Cancer. 1998 Apr 15;82(8):1482-6 [9554524.001]

[Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]

[Cites] Virchows Arch. 2003 Aug;443(2):133-8 [12844262.001]

[Cites] Arch Surg. 2005 Sep;140(9):881-6; discussion 886-7 [16172297.001]

[Cites] Br J Surg. 1989 Nov;76(11):1165-7 [2688803.001]

[Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]

[Cites] Dis Colon Rectum. 1999 Feb;42(2):143-54; discussion 154-8 [10211489.001]

[Cites] Scand J Gastroenterol. 2005 Jul;40(7):858-61 [16109663.001]

(PMID = 18612817.001).

[ISSN] 1573-2568

[Journal-full-title] Digestive diseases and sciences

[ISO-abbreviation] Dig. Dis. Sci.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] P53 and heat shock protein 70 expressions in colorectal adenocarcinoma.

OBJECTIVE: To examine the localization and over expression of heat shock protein 70 (HSP70) and p53 in patients with colorectal cancer and compared it with control tissue (including normal colon tissue).

METHODS: This was a retrospective study of 60 patients with colorectal adenocarcinoma at the Jordan University of Science and Technology (JUST), Irbid, Jordan from 1997 to 2000.

Immuno-histochemistry showed that over expression of HSP70 had no statistically significant difference with any of the different prognostic factors assessed, mainly the grade and the stage.

Control tissue (normal colon) was negative, p53, cell-cycle-related oncogene product, was strongly over expressed in the nuclei of the cancer cells of the cancer tissue.

We found no significant difference in terms of size, patient age, lymph node state, and stage.

[MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Colorectal Neoplasms / pathology. HSP70 Heat-Shock Proteins / metabolism. Tumor Suppressor Protein p53 / metabolism

MedlinePlus Health Information. consumer health - Colorectal Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16228064.001).

[ISSN] 0379-5284

[Journal-full-title] Saudi medical journal

[ISO-abbreviation] Saudi Med J

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Saudi Arabia

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HSP70 Heat-Shock Proteins; 0 / Tumor Suppressor Protein p53

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Simultaneous laparoscopic descending colectomy and nephroureterectomy for descending colon carcinoma and left ureteral carcinoma: report of a case.

To our knowledge, there is no case report of the synchronous resection of colon and ureteral carcinomas by laparoscopy, because of the rareness of this combination and the technical difficulties involved.

We report a case of simultaneous descending colon and left ureteral carcinomas, both of which were judged to be relatively early stage carcinoma, which we resected successfully laparoscopically.

[MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Colonoscopy. Humans. Laparoscopy. Male. Urography

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4 [17893502.001]

[Cites] Surg Today. 2007;37(11):1004-8 [17952536.001]

[Cites] Am J Clin Oncol. 2000 Aug;23(4):364-70 [10955865.001]

[Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]

[Cites] Surg Laparosc Endosc Percutan Tech. 2007 Aug;17 (4):283-6 [17710049.001]

[Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]

[Cites] Dis Colon Rectum. 2006 Oct;49(10 Suppl):S30-6 [17106813.001]

[Cites] J Laparoendosc Adv Surg Tech A. 2004 Jun;14(3):179-81 [15245672.001]

[Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]

[Cites] J Urol. 2005 Apr;173(4):1102-7 [15758710.001]

[Cites] Can J Surg. 2007 Feb;50(1):48-57 [17391617.001]

[Cites] Int J Colorectal Dis. 2006 Jan;21(1):92-3 [15668786.001]

[Cites] Surg Laparosc Endosc Percutan Tech. 2003 Dec;13(6):382-6 [14712100.001]

[Cites] J Laparoendosc Adv Surg Tech A. 2006 Jun;16(3):297-300 [16796445.001]

[Cites] Urology. 2001 Jan;57(1):133-7 [11164158.001]

(PMID = 19639445.001).

[ISSN] 1436-2813

[Journal-full-title] Surgery today

[ISO-abbreviation] Surg. Today

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Cancers were staged according to the Dukes classification (Stage A in 41 percent, Stage B in 28 percent, and Stage C in 31 percent; median distance from the anal margin, 3 (range, 1-5) cm).

[MeSH-major] Adenocarcinoma / surgery. Adenoma, Villous / surgery. Anal Canal / surgery. Carcinoid Tumor / surgery. Colectomy / methods. Rectal Neoplasms / surgery

Genetic Alliance. consumer health - Rectal Cancer.

MedlinePlus Health Information. consumer health - Carcinoid Tumors.

Hazardous Substances Data Bank. FLUOROURACIL .

Hazardous Substances Data Bank. LEUCOVORIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16086223.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil